Civica Rx to launch 20 generic drugs in 2019

A new not-for-profit startup aimed at producing generic drugs will introduce 20 products in 2019, Reuters reported. The supplier, Civica Rx, initially expected to offer just 14 drugs in 2019, but will now likely exceed that after working with companies to produce additional medicines, company officials told Reuters.

Civica Rx was launched in September 2018 by several health foundations and hospital systems, including Intermountain Healthcare, Mayo Clinic, Trinity Health and more, to develop generic drugs that would address drug shortages and counter rising drug prices. The group has raised more than $160 million from its members, Reuters reported.

Over the next three to five years, Civica Rx plans to offer up to 100 generic medicines that are critical to its member hospitals. Member hospitals will pay the cost of drugs purchased and a fee to Civica based on their size, according to Reuters. The first medicines will be available at locations in New Jersey, Pennsylvania and North Carolina, and the group is negotiating prices with manufacturers in return for commitments to purchase the products for five to 10 years.

U.S. hospitals have faced severe shortages of commonly-used medicines, including anesthetics, intravenous saline and chemotherapies, over the last few years, sometimes accompanied by steep price increases. Hospitals have faced deep impacts from rising drug costs and shortages, according to a recent report, even turning to alternative therapies and treatments to accommodate.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup